Evidence reviewed: 8 November 2026. Fibromyalgia is a chronic condition involving generalized pain, fatigue, unrefreshing sleep, concentration difficulties (“fibro fog”) and sometimes mood or gastrointestinal symptoms. It is associated with altered nociceptive and central pain processing rather than simply inflammation or injury in individual muscles. Fibromyalgia is not diagnosed by counting tender points alone; modern criteria consider pain distribution, symptom severity and duration. Treatment usually combines education, carefully paced exercise, psychological support and medicines when appropriate. In a significant 2025 update, the US FDA approved sublingual cyclobenzaprine (Tonmya) for adults with fibromyalgia, adding a fourth specifically approved U.S. drug option alongside pregabalin, duloxetine and milnacipran [1–5].
What is fibromyalgia?
Fibromyalgia is a chronic widespread pain syndrome often accompanied by abnormal sensory amplification. Everyday pressure or exertion may feel unusually painful; minor stressors or poor sleep can increase symptoms. The underlying processes are complex and involve central pain modulation, neurotransmitter systems, autonomic signaling, sleep regulation and other interacting factors [1,2].
Fibromyalgia is real even when routine imaging, blood tests or inflammatory markers are normal. It is not equivalent to malingering, and is not simply a psychiatric disorder. However, depression, anxiety, sleep apnea, arthritis and other conditions can coexist and should be evaluated when suggested by the history.
Common symptoms
- Chronic generalized pain affecting multiple regions of the body, sometimes shifting in intensity or location.
- Persistent fatigue or feeling exhausted after routine activities.
- Unrefreshing sleep, insomnia or disturbed sleep patterns.
- Cognitive symptoms, including word-finding difficulty, mental fatigue and impaired concentration (“fibro fog”).
- Heightened sensitivity to pressure, touch, noise or temperature in some patients.
- Headaches, abdominal discomfort, irritable bowel-type symptoms or pelvic pain in some cases.
- Mood symptoms, anxiety or reduced quality of life, which may be either contributors or consequences of chronic illness.
Symptoms fluctuate: some patients have good and bad days, and others experience sustained disability. A symptom flare does not necessarily imply permanent tissue damage or progression to a destructive inflammatory disease.
Updated diagnostic criteria: tender points are no longer required
Older criteria emphasized finding at least 11 tender points out of 18. That examination is not required under the 2016 revised American College of Rheumatology (ACR) criteria, which instead assess Widespread Pain Index (WPI), Symptom Severity Scale (SSS), generalized pain distribution and at least three months of symptoms [1,2].
| 2016 ACR diagnostic element | Criterion |
|---|---|
| WPI and SSS | WPI ≥7 with SSS ≥5, or WPI 4–6 with SSS ≥9. |
| Generalized pain | Pain in at least 4 of 5 defined body regions. Jaw, chest and abdominal pain are not counted toward this particular generalized-pain distribution definition. |
| Symptom duration | Symptoms present at a similar level for at least 3 months. |
| Coexisting illness | Fibromyalgia can be diagnosed alongside another clinically important condition, rather than requiring every alternative condition to be excluded first. |
The WPI ranges from 0 to 19 and records painful sites; the SSS ranges from 0 to 12 and covers fatigue, unrefreshing sleep, cognition and selected additional symptoms. A clinician interprets them in context; these are standardized classification/diagnostic tools, not a universal online self-diagnosis [1,2].
How is fibromyalgia evaluated?
A clinician reviews pain distribution, fatigue, sleep, function, mood, medicines and neurologic or inflammatory warning signs. Examination may assess tender areas, joints, neurological function and features of alternate or coexisting conditions. No single blood test or MRI confirms fibromyalgia. Laboratory testing is targeted rather than an extensive default “fibromyalgia panel” [1,2].
Depending on clinical findings, evaluation may include complete blood count, thyroid testing, selected inflammatory markers, vitamin deficiency testing or evaluation for sleep apnea. Unexpected abnormalities should be investigated rather than automatically attributed to fibromyalgia. The condition can coexist with rheumatoid arthritis, osteoarthritis, hypothyroidism or other chronic disease.
Warning signs that warrant a different evaluation
Unexplained fever, significant weight loss, progressive objective weakness, focal neurologic deficits, joint swelling/redness, major new bowel or bladder dysfunction, malignancy-related symptoms or rapid functional decline require further assessment. Fibromyalgia does not itself explain every new symptom, and serious disease should not be dismissed because a patient already carries the diagnosis.
Sudden chest pain, fainting, severe shortness of breath or new stroke-like symptoms are emergencies, not ordinary pain flares.
What causes fibromyalgia?
Research implicates a mix of central sensitization/nociplastic pain, altered descending pain inhibition, changes in sleep and stress physiology, and genetic or environmental influences [1]. Some individuals report onset after an infection, physical trauma or prolonged stress; others have no clear trigger.
Although neurotransmitters such as serotonin, norepinephrine, glutamate and substance P have been studied, there is no validated single neurotransmitter imbalance explaining all fibromyalgia cases. Fibromyalgia is not an autoimmune disease in the conventional sense, and routine disease-modifying antirheumatic drugs (DMARDs) do not treat it unless the patient also has a separate inflammatory condition.
The overall treatment strategy
The EULAR recommendations and current clinical reviews emphasize education, individualized exercise and patient-centered nonpharmacological approaches as foundational. Medicines may help selected symptoms but rarely eliminate pain, fatigue and sleep problems completely [1,3].
| Goal | Potential approach | Expected benefit |
|---|---|---|
| Improve daily function | Paced aerobic and strengthening activity. | Improved endurance, mobility and confidence over time. |
| Reduce pain interference | Education, CBT or ACT, targeted medicines when appropriate. | Better coping and function rather than necessarily zero pain. |
| Improve sleep | Assess and treat insomnia or sleep apnea, consider CBT-I where needed. | Improved restorative sleep and symptom management. |
| Address fatigue and cognitive issues | Pacing, activity balance, sleep support and medication review. | Better consistency in daily activities and reduced adverse drug effects. |
| Improve mood and quality of life | Psychotherapy, social support and treatment for coexisting disorders. | Reduced distress and improved participation. |
Exercise: gradual progress, not forced overexertion
Aerobic exercise and strengthening activities have evidence of benefit in fibromyalgia, and EULAR strongly recommends exercise as a core intervention [3]. The right starting point depends on severity and capacity. Examples include short walks, water-based movement, gentle cycling, stretching or supervised resistance training.
Start low and progress gradually. A person who is severely deconditioned may need only a few minutes or very light activity initially, while another patient can use a more structured program. Repeatedly forcing patients through severe symptom exacerbation is not appropriate. Those with marked post-exertional symptom worsening should be evaluated for coexisting conditions and given individualized pacing strategies.
CBT, ACT and self-management
Cognitive behavioral therapy (CBT) and acceptance and commitment therapy (ACT) can help some patients reduce pain-related distress and avoidance, improve sleep and develop a more workable relationship with symptoms. These approaches do not imply pain is invented or merely psychological. Psychological therapies support nervous-system regulation and practical coping [3,4].
Education may focus on planning activity, managing flares, breaking long tasks into smaller periods, sleep regularity and reviewing unhelpful beliefs that trigger overexertion or fear. The person’s own goals—such as returning to work, studying or being able to manage household tasks—should guide treatment evaluation.
How do fibromyalgia medicines differ?
Medication may be considered when nonpharmacological care is insufficient or particular symptoms cause substantial impairment. Drug approvals and guideline recommendations differ by country and by the type of chronic pain population studied. In the United States, pregabalin, duloxetine, milnacipran and, since 2025, sublingual cyclobenzaprine (Tonmya) have FDA approval for fibromyalgia treatment in adults [4,5].
| Medicine | Mechanism/role | Important adverse effects or cautions |
|---|---|---|
| Pregabalin | Alpha-2-delta calcium-channel ligand; may reduce pain and improve sleep in selected patients. | Dizziness, somnolence, edema, weight gain, dependence/misuse potential, renal dose adjustment. |
| Duloxetine | SNRI, increases serotonin/norepinephrine signaling involved in pain modulation. | Nausea, blood-pressure effects, sexual adverse effects, drug interactions and withdrawal risk. |
| Milnacipran | SNRI approved for fibromyalgia in the United States. | Nausea, increased pulse/BP, sweating, interactions and serotonin-related concerns. |
| Tonmya: sublingual cyclobenzaprine | FDA-approved 2025 for adult fibromyalgia; bedtime therapy with central pain and sleep-related effects. | Mouth numbness/irritation, taste changes, sedation, cardiac and serotonergic contraindications, pregnancy precautions. |
| Low-dose amitriptyline | Off-label option sometimes considered for pain/sleep in selected patients. | Anticholinergic symptoms, dizziness, possible cardiac effects, overdose toxicity. |
FDA approval is not proof that a medicine works for everyone. Average pain reduction can be modest, treatment response varies, and side effects influence continuation. Combining several sedating drugs can increase falls and respiratory risk. No single medicine is a proven cure for fibromyalgia.
New in 2025: FDA approval of Tonmya
On 15 August 2025, the FDA approved Tonmya (cyclobenzaprine hydrochloride sublingual tablets) for fibromyalgia in adults. This is a specific under-the-tongue formulation, not blanket approval of every ordinary oral cyclobenzaprine tablet as a fibromyalgia treatment [5,6].
According to the FDA prescribing information, the usual adult schedule starts with 2.8 mg sublingually at bedtime for the first 14 days, then 5.6 mg at bedtime thereafter if appropriate. The label specifies different maximum dosing in older adults and patients with mild hepatic impairment; it is not recommended in moderate/severe hepatic impairment [5]. Patients should not start or adjust this drug from an article.
Important Tonmya precautions: It is contraindicated with MAO inhibitors or within 14 days of stopping them, and in certain arrhythmias, cardiac conduction disease, heart failure, recent myocardial infarction recovery and hyperthyroidism. It can cause drowsiness and mouth-related adverse effects, and has significant pregnancy, serotonin syndrome and drug-interaction warnings [5].
Its oral mucosal effects can include numbness, unusual taste, mouth discomfort and ulcers. The label advises moistening the mouth with water before use and following administration instructions. The product is not simply a generic sleeping pill or a substitute for appropriate non-drug management.
Pregabalin: benefit and limitations
Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing release of certain excitatory neurotransmitters. It may reduce neuropathic-like pain and improve sleep in some fibromyalgia patients. However, dizziness, somnolence, edema, weight gain and possible dependence must be considered, especially in older adults or those taking opioids or alcohol [4].
NICE NG193, covering a broader chronic primary pain population, recommends not initiating gabapentinoids for chronic primary pain. This differs from the FDA’s product-specific approval of pregabalin for fibromyalgia and should not be presented as if international guidelines all agree on identical medicine choices [4]. Local clinical guidance, regulatory status and individual circumstances determine prescribing.
Duloxetine and milnacipran
Duloxetine and milnacipran are serotonin–norepinephrine reuptake inhibitors (SNRIs). They can improve pain and function in selected patients, although benefit varies. Potential adverse effects include nausea, sweating, blood-pressure or pulse effects and withdrawal symptoms after abrupt cessation [4].
Duloxetine may also be selected when coexisting depression or anxiety is relevant, but the prescription still depends on contraindications, drug interactions and past response. Both agents should be reviewed before adding other serotonergic drugs because of serotonin-toxicity risk.
Why opioids and corticosteroids are usually discouraged
Routine opioid therapy for fibromyalgia is generally discouraged because evidence of sustained benefit is limited while risks include dependence, sedation, overdose, constipation and opioid-induced hyperalgesia. Strong opioids are particularly poor routine choices for nociplastic pain. Systemic corticosteroids are also not standard fibromyalgia therapy because this is not inherently an inflammatory autoimmune disease [3,4].
NSAIDs or paracetamol may be used for separate musculoskeletal or inflammatory problems, but they often do not adequately address the central amplification processes of fibromyalgia. Repeated escalating doses without a defined benefit should be reconsidered.
Sleep disturbances and fibromyalgia
Nonrestorative sleep and chronic insomnia may intensify pain and fatigue. Treatment can include a regular sleep schedule, reducing sleep-disrupting substances, evaluating sleep apnea or restless legs symptoms, and structured CBT for insomnia (CBT-I) when appropriate. Sleep-hygiene tips alone are not considered sufficient treatment for chronic insomnia under the 2025 VA/DoD guidance.
Our companion CBT-I and chronic insomnia treatment guide explains stimulus control, safe behavioral sleep scheduling and medicine limitations.
Is fibromyalgia an autoimmune disease?
Fibromyalgia is not classified as a conventional inflammatory autoimmune condition, and routine tests for rheumatoid arthritis or lupus may be normal. However, fibromyalgia can coexist with autoimmune arthritis or other diseases. New objective swollen joints, fevers, rashes or abnormal inflammatory findings deserve assessment rather than being attributed to fibromyalgia without evaluation [1,2].
DMARDs such as methotrexate target selected inflammatory diseases and are not fibromyalgia treatments on their own. A patient with both rheumatoid arthritis and fibromyalgia may need separate treatment of each condition.
Fibromyalgia in women, men and other groups
Fibromyalgia has historically been more often diagnosed in women, but it can affect men and people of any gender. Differences in health-seeking, symptoms and diagnostic history may influence recognition. Children and adolescents can have chronic widespread pain syndromes, but the adult medication approvals and diagnostic approaches should not be copied directly into pediatric care.
Pregnancy and breastfeeding require specific medication reviews, especially when medicines carry reproductive warnings. A person should not abruptly stop all regular medicines without consulting the prescriber.
Managing symptom flares
Flares can be associated with poor sleep, infection, emotional stress, overactivity or changes in routine, although triggers are individual. During a flare, temporarily reduce demanding activity while maintaining gentle movement within tolerance; prioritize hydration, rest and symptom-specific care.
Flare management is not complete bed rest for weeks. Reassess for new illness if pain changes significantly, becomes focal with neurological symptoms or is accompanied by fever or other red flags. A clinician can help adjust pacing, sleep treatment or medication where needed.
Setting realistic treatment goals
Clinically useful goals include more consistent sleep, less pain interference, better stamina, improved concentration, greater participation in work or relationships and reduced medication side effects. Symptom scores and patient-reported function can help measure progress, but no one outcome defines recovery.
Some people improve substantially with coordinated care, while others need long-term adjustments. Patient-centered management means taking symptoms seriously, sharing decisions and avoiding promises of a complete quick cure.
Frequently asked questions
Are 11 of 18 tender points still required?
No. The 2016 revised ACR criteria use pain distribution, symptom severity and duration; tender-point counting is no longer mandatory [1,2].
Can fibromyalgia be diagnosed if a person also has arthritis?
Yes. The revised criteria allow coexisting conditions, although new concerning symptoms must still be investigated [1].
Does a normal inflammatory blood test prove fibromyalgia?
No. Tests may help identify other illnesses, but there is no single confirmatory fibromyalgia blood test.
How many FDA-approved fibromyalgia medicines were available in 2026?
Four specific U.S. drug options: pregabalin, duloxetine, milnacipran and the 2025-approved sublingual cyclobenzaprine product Tonmya [5].
Is ordinary cyclobenzaprine interchangeable with Tonmya?
No. Tonmya is a specific FDA-approved sublingual formulation, with its own administration and safety guidance [5].
Should everyone with fibromyalgia use pregabalin?
No. Benefit and adverse effects vary, and guideline approaches differ; non-drug care is foundational [3,4].
Can exercise cure fibromyalgia?
Exercise can improve symptoms and function but is not a guaranteed cure. Start at a tolerable level and adjust to individual response.
Key takeaways
Fibromyalgia involves widespread pain and associated fatigue, sleep and cognitive symptoms. Diagnosis follows modern ACR pain-distribution and symptom-severity criteria, not mandatory tender-point counts. Education, graded activity, CBT/ACT and sleep care form the foundation; medicines can be useful selectively. The 2025 FDA approval of Tonmya added a new treatment option, but it has important cardiac, reproductive, mouth-related and sedative risks.
References
- Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46:319–329. Diagnostic criteria table.
- Disentangling diagnosis and management of fibromyalgia. Clinical review with revised diagnostic framework. 2023.
- Macfarlane GJ, Kronisch C, Atzeni F, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76:318–328. PubMed.
- National Institute for Health and Care Excellence. Chronic primary pain: assessment and management (NG193). NICE; 2021.
- US Food and Drug Administration. Tonmya (cyclobenzaprine hydrochloride sublingual tablets): prescribing information. Revised June 2026.
- Tonix Pharmaceuticals. FDA approval announcement for Tonmya, 15 Aug 2025.
Medical disclaimer: Educational information only. Fibromyalgia symptoms and drug suitability require individualized clinical assessment. Prescription medicine risks include sedation, interactions, pregnancy concerns, blood-pressure changes and kidney or heart-related contraindications. New neurologic deficits, severe chest pain or other emergency symptoms should not be attributed automatically to fibromyalgia.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.